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Abstract
Serine–arginine protein kinase 1 (SRPK1) phosphorylates proteins involved in the regulation of several
mRNA-processing pathways, including alternative splicing. SRPK1 has been recently reported to be overexpressed
in multiple cancers, including prostate cancer, breast cancer, lung cancer, and glioma. Several studies have shown
that inhibition of SRPK1 has anti-tumoural effects, and SRPK1 has therefore become a new candidate for targeted
therapies. Interestingly, in terms of molecular mechanism, SRPK1 seems to act heterogeneously, and has been
reported to affect several processes in different cancers, e.g. angiogenesis in prostate and colon cancer, apoptosis
in breast and colon cancer, and migration in breast cancer. A recent report adds to this puzzle, showing that the
main effect of SRPK1 overexpression in non-small-cell lung carcinoma is to stimulate a stem cell-like phenotype.
This pleiotropy might be related to preferential activation of different downstream signalling pathways by SRPK1
in various cancers.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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The transformation of a normal human cell into can-
cer is a highly complex process that involves the accu-
mulation of mutations alongside a plethora of complex
non-genetic mechanisms. It is now understood that these
processes culminate in the development of a heteroge-
neousmix of genetically distinct subclones that, together
with endothelial, stromal and various other infiltrating
cell types, collectively make up a tumour [1,2]. Fur-
ther evaluation of the hierarchical organization of several
tumour types has led to the identification of a subpopula-
tion of self-renewing cells that show stem-cell like prop-
erties, the so-called cancer stem cells (CSCs), which are
thought to be important in the development of tumour
recurrence, metastasis and resistance to therapy [3].
Serine–arginine protein kinase 1 (SRPK1) is a pro-
tein kinase that specifically phosphorylates proteins con-
taining serine–arginine-rich (SR) domains. SR proteins
are involved in regulating several RNA-processing path-
ways, including RNA stability, alternative splicing, and
translation [4]. Both SRPK1 and its downstream targets
have been shown to be involved in a number of biologi-
cal and pathological processes, with increased expres-
sion being seen in a range of cancer types, including
breast, colon, pancreas and prostate cancer [5–7]. In
their recent article, Gong et al [8] explored the role of
SRPK1 in the promotion of a CSC-like phenotype in
human non-small-cell lung carcinoma (NSCLC).
First, Gong et al [8] demonstrated that SRPK1mRNA
levels are elevated in NSCLC patients as compared with
normal individuals, with expression being increased in
NSCLC lines relative to that of normal lung epithelial
cells and non-cancerous adjacent tissues. They went
on to use immunohistochemistry to evaluate relative
expression levels of SRPK1 in human NSCLC tissues.
Statistical analyses demonstrated SRPK1 to be strongly
associated with clinical stage and TNM classification,
with high levels being linked to shorter overall survival
than in patients with low-level expression. This associ-
ation remained true when samples grouped according
to clinical stage were compared; this, when combined
with SRPK1 expression being an independent prognos-
tic factor in multivariate analyses, led the authors to
assert that SRPK1 levels may be useful as a prognostic
indicator in NSCLC [8].
CSCs have been implicated in the development of
drug resistance in NSCLC [9]. Therefore, the authors
undertook a series of well-designed in vitro experi-
ments exploring the potential role of SRPK1 in the
promotion of the CSC phenotype. They found that
SRPK1-transduced cells expressed higher levels
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of pluripotency-associated markers, and showed
Hoescht33342 dye exclusion (a marker for cancer
stem cells) and greater self-renewal capacity [8]. The
use of SRPK1-specific RNA interference oligonu-
cleotides, which suppress expression of the protein,
demonstrated the converse effect, thus suggesting that
SRPK1 promotes stem cell accumulation and adoption
of a stem cell-like phenotype. A supporting set of in
vivo experiments on BALB/c nude mice showed that
tumours formed by SRPK1-transduced NSCLC cells
were larger than those formed by controls, with the
opposite being observed when SRPK1-silenced cells
were inoculated.
Finally, through the use of gene set enrichment
analysis, a luciferase reporter assay for T-cell fac-
tor/lymphoid enhancer factor transcriptional activity,
immunofluorescence, and polymerase chain reaction
of downstream gene targets, Gong et al [8] sought to
determine whether the underlying mechanisms of stem
cell phenotype development are linked with SRPK1
action on the Wnt–β-catenin pathways, which have pre-
viously been implicated in the development and activity
regulation of CSCs. Upregulation of SRPK1 led to both
increased beta-catenin translocation to the nucleus and
increased transcriptional activity in NSCLC cell lines,
leading them to conclude that it is through activation of
this signalling pathway that SRPK1 exerts its effect on
the promotion of stemness [8].
SRPK1 in other cancers: mechanistic differences
Not only does this article implicate SRPK1 in yet
another cancer type, but the findings are of particular
interest because they demonstrate an alternative
mechanism by which SRPK1 exerts its tumouri-
genic effects. Much of the previous research on SRPK1
has focused on its role in the regulation of pre-mRNA
splicing. SRPK1 contains a PKc superfamily kinase
domain, and is able to phosphorylate SR proteins,
thereby regulating their functional activity. These
proteins have been shown to play an important role
in alternative pre-mRNA splicing, as well as other
steps of RNA metabolism, such as polymerase II
transcription, nuclear export of mature mRNA, and
nonsense-mediated mRNA decay [10,11]. The archety-
pal member of the SR protein family and a key substrate
of SRPK1 is serine–arginine-rich splicing factor 1
(SRSF1), a proto-oncogene that appears to exert its
tumorigenic effects via a number of mechanisms,
particularly alternative pre-mRNA splicing [10]. One
pre-mRNA splicing event for which SRSF1 has been
shown to be a key regulator is that of vascular endothelial
growth factor A (VEGF-A) (a regulator of angiogenesis)
to form pro-angiogenic and anti-angiogenic isoforms
[12]. In our recently published study, we found that
increased SRPK1–SRSF1 axis activity in prostate
cancer led to preferential splicing of pro-angiogenic
VEGF-A mRNA, thereby implicating modulation
of angiogenesis as an important mechanism in the
pathogenesis of this cancer subtype [6] (Figure 1).
Interestingly, although SRPK1 expression also
appears to be increased in breast cancer [5], contempo-
rary work seems to suggest an alternative mechanism of
pathogenesis in this tumour type. In their recent study,
van Roosmalen et al [13] found that SRPK1 expression
correlated with preferential metastasis of breast cancer
to the lungs and brain. Subsequent SRPK1 knockdown
appeared to suppress metastasis to distant organs, and
to inhibit focal adhesion reorganization, suggesting
Figure 1. Examples of pleiotropic effects of SRPK1 in various cancers. Depending on the type of cancer, SRPK1 regulates different cellular
properties. Akt, protein kinase B; FAK, focal adhesion kinase; MAPK, mitogen-activated protein kinase. P denotes phosphorylation.
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that its activity and function are fundamental to tumour
cell migration in this particular cancer type [13]. Addi-
tionally, work published by Lin et al also suggests that
SRPK1 may exert some of its tumourigenic effects
in breast cancer through RNA-binding motif protein
4-mediated reduction in the expression of pro-apoptotic
IR-B and MCL-1S transcripts, thereby modulating
sensitivity to apoptotic signals [14].
The conclusion of the Gong et al study that SRPK1
promotes the development of a stem cell-like phenotype
in NSCLC suggests yet another mechanism of SRPK1
action in this cancer type [8]. Interestingly, although the
authors assert that promotion of this phenotype may be
due to SRPK1-mediated activation of Wnt–β-catenin
pathways, the exact mechanism that drives the activation
remains to be elucidated. One possibility, as suggested
by extrapolation of the findings of a recent study [15],
is that SRPK1 upregulation may lead to increased phos-
phorylation of SR proteins such as SRSF1, which in turn
recruit β-catenin mRNA and enhance its translation in
an mTOR-dependent manner. Although, to date, there
have been no specific in-depth studies of the relationship
between SRPK1 and angiogenesis in lung cancer, these
findings may indicate that SRPK1 preferentially drives a
particular pattern of gene expression that is dependent on
cancer type, thereby leading to a different predominant
phenotypic picture in each. It is possible that SRPK1
activates different downstream signalling pathways in
different cancers, thereby resulting in various cellular
processes being affected (Figure 1). This effect may be
due to phosphorylation of different SR proteins, which
may be tissue-specific and cell-specific in each cancer.
Interestingly, a recent study has revealed a complex
relationship between SRPK1 and another kinase,
CDC2-like kinase 1 (CLK1) [a member of the
CDC2-like kinase (CLK) family], in the regula-
tion of SR protein phosphorylation [16]. Unlike the
serine–arginine protein kinases such as SRPK1, which
are only able to phosphorylate Arg–Ser dipeptides,
the CLKs are localized strictly within the nucleus, and
are able to phosphorylate both Arg–Ser and Ser–Pro
dipeptides. A symbiotic relationship between SRPK1
and CLK1 has been demonstrated, with binding of
SRPK1 to an RS-like domain in the N-terminus of
CLK1 facilitating release of phosphorylated SR pro-
teins, and hence subsequent splice-site recognition and
spliceosome assembly [16]. With this relationship in
mind, it would be interesting to investigate whether
CLK1 levels and/or activity vary across different cancer
types and consequently modulate SRPK1 function.
SRPK1 as a therapeutic target in cancer
As well as its potential use as a biomarker, the emerging
evidence supporting the role of SRPK1 in the patho-
genesis of several cancers, irrespective of its underlying
mechanism, makes it a possible and indeed attractive
therapeutic target. Although more research is needed to
fully elucidate the biology of SRPK1 and its downstream
target pathways, early data concerning the potential
advantages of its inhibition seem encouraging. For
example, in a therapeutic proof-of-principle experi-
ment in the field of prostate cancer, we found that
the SRPK1 inhibitors were able to inhibit phosphory-
lation of SR proteins and switch VEGF-A splicing in
vitro [6]. Furthermore, we demonstrated that one of
the agents, SPHINX, decreased tumour growth when
administered intraperitoneally to a mouse model of
orthotopic prostate cancer.
It is hoped that the publication of further high-quality
studies, such as the one presented by Gong et al [8],
will allow us to gain a more in-depth understanding of
the mechanisms underlying the apparent role of SPRK1
in cancer biology. In doing so, they may provide the
basis for ongoing drug development and, eventually,
clinical trials. Furthermore, if indeed the mechanistic
differences between tumour types persist as more stud-
ies emerge, we may see variation in the clinical role of
small-molecule SRPK1 inhibitors, depending on cancer
type. For example, perhaps they may be used to stave
off metastases in patients with early breast cancer, and
be used as anti-angiogenic therapy in prostate cancer
(Figure 1).
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